Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination

Daniel J Walker, Melissa P DelBello, John Landry, Deborah N D'Souza, Holland C Detke, Daniel J Walker, Melissa P DelBello, John Landry, Deborah N D'Souza, Holland C Detke

Abstract

Background: We examined the efficacy of olanzapine/fluoxetine combination (OFC) in improving health-related quality of life (QoL) in the treatment of bipolar depression in children and adolescents.

Methods: Patients aged 10-17 years with bipolar I disorder, depressed episode, baseline children's depression rating scale-revised (CDRS-R) total score ≥40, Young Mania Rating Scale (YMRS) total score ≤15, and YMRS-item 1 ≤ 2 were randomized to OFC (6/25-12/50 mg/day olanzapine/fluoxetine; n = 170) or placebo (n = 85) for up to 8 weeks of double-blind treatment. Patients and parents completed the revised KINDL questionnaire for measuring health-related QoL in children and adolescents (KINDL-R) at baseline and endpoint. The mean change in CDRS-R total and item scores were used to compare improvement in symptomatology in patients taking OFC and placebo. Tests were 2-sided using a Type I error cutoff of 0.05, and no adjustments for multiple comparisons were made.

Results: Baseline QoL as measured by the KINDL-R was substantially impaired relative to published norms for a healthy school-based sample. OFC-treated patients demonstrated an improvement over placebo at endpoint with respect to mean change from baseline in the patient-rated KINDL-R Self-esteem subscale score (p = 0.028), and in the parent KINDL-R ratings of emotional well-being (p = 0.020), Self-esteem (p = 0.030), and Family (p = 0.006). At endpoint, OFC-treated patients still had a lower QoL compared to the normative population. OFC showed significant improvement (p ≤ 0.05) versus placebo on the CDRS-R total score and on 7 of the 17 CDRS-R items.

Conclusions: Patients aged 10-17 years with an acute episode of bipolar depression and their parents reported greater improvements (parents noticed improvements in more areas than did their offspring) on some aspects of QoL when treated with OFC compared with placebo. However, after 8 weeks of treatment, KINDL-R endpoint scores remained lower than those of the, presumably healthy, control population. Clinical trial registration information A Study for Assessing Treatment of Patients Ages 10-17 with Bipolar Depression; http://www.clinicaltrials.gov; NCT00844857.

Keywords: Adolescents; Bipolar; Children; Depression; Olanzapine fluoxetine combination; Quality of life.

Figures

Fig. 1
Fig. 1
Changes in KINDL-R patient scale from baseline to endpoint relative to the normative data for adolescent males and adolescent females [32]. The upper and lower edge of each box represents the ‘mean plus one standard deviation’, and the ‘mean minus one standard deviation’ respectively, the lines above and below each box represent the ‘mean plus two standard deviations’, and the ‘mean minus two standard deviations’ respectively. The line across the middle of each box represents the mean. KINDL-R KINDL questionnaire for measuring health-related quality of life in children and adolescents, OFC olanzapine/fluoxetine combination, PBO placebo

References

    1. Blader JC, Carlson GA. Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996–2004. Biol Psychiatry. 2007;62:107–114. doi: 10.1016/j.biopsych.2006.11.006.
    1. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry. 2007;64:1032–1039. doi: 10.1001/archpsyc.64.9.1032.
    1. Van Meter AR, Moreira AL, Youngstrom EA. Meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry. 2011;72:1250–1256. doi: 10.4088/JCP.10m06290.
    1. Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A) J Am Acad Child Adolesc Psychiatry. 2010;49:980–989. doi: 10.1016/j.jaac.2010.05.017.
    1. Lofthouse N, Fristad MA. Psychosocial interventions for children with early-onset bipolar spectrum disorder. Clin Child Fam Psychol Rev. 2004;7:71–88. doi: 10.1023/B:CCFP.0000030286.75522.5f.
    1. Freeman AJ, Youngstrom EA, Michalak E, Siegel R, Meyers OI, Findling RL. Quality of life in pediatric bipolar disorder. Pediatrics. 2009;123:e446–e452. doi: 10.1542/peds.2008-0841.
    1. Gomes BC, Kleinman A, Carvalho AF, Pereira TC, Gurgel AP, Lafer B, et al. Quality of life in youth with bipolar disorder and unaffected offspring of parents with bipolar disorder. J Affect Disord. 2016;202:53–57. doi: 10.1016/j.jad.2016.05.041.
    1. Simon GE. Social and economic burden of mood disorders. Biol Psychiatry. 2003;54:208–215. doi: 10.1016/S0006-3223(03)00420-7.
    1. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20:139–154. doi: 10.1185/030079903125002801.
    1. Kleinman NL, Brook RA, Rajagopalan K, Gardner HH, Brizee TJ, Smeeding JE. Lost time, absence costs, and reduced productivity output for employees with bipolar disorder. J Occup Environ Med. 2005;47:1117–1124. doi: 10.1097/01.jom.0000177048.34506.fc.
    1. Sierra P, Livianos L, Rojo L. Quality of life for patients with bipolar disorder: relationship with clinical and demographic variables. Bipolar Disord. 2005;7:159–165. doi: 10.1111/j.1399-5618.2005.00186.x.
    1. Altshuler LL, Post RM, Black DO, Keck PE, Jr, Nolen WA, Frye MA, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67:1551–1560. doi: 10.4088/JCP.v67n1009.
    1. Samalin L, Tixeront C, Llorca PM. Asénapine dans le trouble bipolaire: efficacité, tolérance et utilisation en pratique clinique [Asenapine in bipolar disorder: efficacy, safety and place in clinical practice] Encephale. 2012;38:257–265. doi: 10.1016/j.encep.2012.05.001.
    1. Caresano C, Di Sciascio G, Fagiolini A, Maina G, Perugi G, Ripellino C, et al. Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context. Adv Ther. 2014;31:873–890. doi: 10.1007/s12325-014-0139-3.
    1. Detke HC, DelBello MP, Landry J, Usher RW. Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2015;54:217–224. doi: 10.1016/j.jaac.2014.12.012.
    1. Poznanski EO, Mokros HB. Children’s depression rating scale-revised: manual. Los Angeles: Western Psychological Services; 1996.
    1. Symbyax (olanzapine and fluoxetine hydrochloride) US prescribing information. Indianapolis, IN: Eli Lilly and Company, 2015. . Accessed 10 Dec 2015.
    1. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:213–235. doi: 10.1097/00004583-200503000-00006.
    1. Pfeifer JC, Kowatch RA, DelBello MP. The use of antipsychotics in children and adolescents with bipolar disorders. Expert Opin Pharmacother. 2007;8:2673–2687. doi: 10.1517/14656566.8.16.2673.
    1. Findling RL, Nyilas M, Forbes RA, McQuad RD, Jin N, Iwamoto T, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70:1441–1451. doi: 10.4088/JCP.09m05164yel.
    1. Rademacher J, DelBello MP, Adler C, Stanford K, Strakowski SM. Health-related quality of life in adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol. 2007;17:97–103. doi: 10.1089/cap.2006.0049.
    1. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60–70. doi: 10.1097/CHI.0b013e3181900404.
    1. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547–1556. doi: 10.1176/appi.ajp.2007.06111932.
    1. Olsen BT, Ganocy SJ, Bitter SM, Findling RL, Case M, Chang K, et al. Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine. Compr Psychiatry. 2012;53:1000–1005. doi: 10.1016/j.comppsych.2012.03.010.
    1. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031–1037. doi: 10.1001/archpsyc.1997.01830230069010.
    1. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205–1215. doi: 10.1097/00004583-200210000-00010.
    1. Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Fluoxetine Pediatric OCD Study Team et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001;40:773–779. doi: 10.1097/00004583-200107000-00011.
    1. Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, et al. TADS team: functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS) J Am Acad Child Adolesc Psychiatry. 2006;45:1419–1426. doi: 10.1097/01.chi.0000242229.52646.6e.
    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. Fourth edition text revision (DSM-IV-TR) Washington DC: American Psychiatric Association; 2000.
    1. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–988. doi: 10.1097/00004583-199707000-00021.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435. doi: 10.1192/bjp.133.5.429.
    1. Ravens-Sieberer U, Bullinger M. KINDL: questionnaire for measuring health-related quality of life in children and adolescents. Munich: Ravens-Sieberer & Bullinger; 2000.
    1. Bullinger M, von Mackensen S, Kirchberger I. KINDL-ein Fragebogen zur Erfassung der gesundheitsbezogenen Lebensqualität von Kindern. Zeitschrift für Gesundheitspsychologie. 1994;2:64–77.
    1. Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. Qual Life Res. 1998;7:399–407. doi: 10.1023/A:1008853819715.
    1. Findling RL, Pathak S, Earley WR, Liu S, DelBello MP. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2014;24:325–335. doi: 10.1089/cap.2013.0105.
    1. Emslie GJ, Prakash A, Zhang Q, Pangallo BA, Bangs ME, March JS. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014;24:170–179. doi: 10.1089/cap.2013.0096.
    1. Mayes TL, Bernstein IH, Haley CL, Kennard BD, Emslie GJ. Psychometric properties of the children’s depression rating scale-revised in adolescents. J Child Adolesc Psychopharmacol. 2010;20:513–516. doi: 10.1089/cap.2010.0063.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2. Hillsdale: Lawrence Erlbaum Associates; 1988.
    1. Taylor J, Jacoby A, Baker GA, Marson AG. Self-reported and parent-reported quality of life of children and adolescents with new-onset epilepsy. Epilepsia. 2011;52:1489–1498. doi: 10.1111/j.1528-1167.2011.03094.x.
    1. Eiser C, Morse R. Can parents rate their child’s health-related quality of life? Results of a systemtic review. Qual Life Res. 2001;10:347–357. doi: 10.1023/A:1012253723272.
    1. Jozefiak T, Larsson B, Wichstrom L. Changes in quality of life among Norwegian school children: a six-month follow-up study. Health Qual Life Outcomes. 2009;7:7. doi: 10.1186/1477-7525-7-7.
    1. Depp CA, Davis CE, Mittal D, Patterson TL, Jeste DV. Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. J Clin Psychiatry. 2006;67:215–221. doi: 10.4088/JCP.v67n0207.
    1. Yen CF, Chen CC, Lee Y, Tang TC, Ko CH, Yen JY. Association between quality of life and self-stigma, insight, and adverse effects of medication in patients with depressive disorders. Depress Anxiety. 2009;26:1033–1039. doi: 10.1002/da.20413.
    1. West AE, Celio CI, Henry DB, Pavuluri MN. Child mania rating scale-parent version: a valid measure of symptom change due to pharmacotherapy. J Affect Disord. 2011;128:112–119. doi: 10.1016/j.jad.2010.06.013.
    1. Meyer M, Oberhoffer R, Hock J, Giegerich T, Müller J. Health-related quality of life in children and adolescents: current normative data, determinants and reliability on proxy-report. J Paediatr Child Health. 2016;52:628–631. doi: 10.1111/jpc.13166.
    1. Weinstein SM, West AE, Pavuluri M. Psychosocial intervention for pediatric bipolar disorder: current and future directions. Expert Rev Neurother. 2013;13:843–850. doi: 10.1586/14737175.2013.811985.
    1. West AE, Weinstein SM, Peters AT, Katz AC, Henry DB, Cruz RA, et al. Child- and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2014;53:1168–1178. doi: 10.1016/j.jaac.2014.08.013.
    1. Hlastala SA, Kotler JS, McClellan JM, McCauley EA. Interpersonal and social rhythm therapy for adolescents with bipolar disorder: treatment development and results from an open trial. Depress Anxiety. 2010;27:457–464. doi: 10.1002/da.20668.
    1. Miklowitz DJ, Axelson DA, Birmaher B, George EL, Taylor DO, Schneck CD, et al. Family-focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial. J Affect Disord. 2004;82(Suppl 1):S113–S128. doi: 10.1016/j.jad.2004.05.020.
    1. Van Meter AR, Henry DB, West AE. What goes up must come down: the burden of bipolar depression in youth. J Affect Disord. 2013;150:1048–1054. doi: 10.1016/j.jad.2013.05.039.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi